Stock Buzzer: Could Sophiris Bio Inc Lose Strenght? The Stock Increases A Lot Today

Stock Buzzer: Could Sophiris Bio Inc Lose Strenght? The Stock Increases A Lot Today

The stock of Sophiris Bio Inc (NASDAQ:SPHS) is a huge mover today! About 795,527 shares traded hands or 4.16% up from the average. Sophiris Bio Inc (NASDAQ:SPHS) has risen 78.38% since April 8, 2016 and is uptrending. It has outperformed by 72.73% the S&P500.
The move comes after 6 months positive chart setup for the $76.87M company. It was reported on Nov, 10 by Barchart.com. We have $7.22 PT which if reached, will make NASDAQ:SPHS worth $119.92 million more.

Analysts await Sophiris Bio Inc (NASDAQ:SPHS) to report earnings on November, 21.

Sophiris Bio Inc (NASDAQ:SPHS) Ratings Coverage

Out of 3 analysts covering Sophiris Bio (NASDAQ:SPHS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Sophiris Bio has been the topic of 3 analyst reports since August 30, 2016 according to StockzIntelligence Inc. The rating was initiated by TH Capital with “Buy” on Thursday, September 15. The firm earned “Overweight” rating on Tuesday, August 30 by Piper Jaffray. Roth Capital initiated the shares of SPHS in a report on Thursday, September 15 with “Buy” rating.

According to Zacks Investment Research, “Sophiris Bio Inc. operates as a biopharmaceutical company. The Company is developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate). It has operations based in San Diego. Sophiris Bio Inc. is based in Canada.”

Insitutional Activity: The institutional sentiment decreased to 0.77 in Q2 2016. Its down 1.98, from 2.75 in 2016Q1. The ratio fall, as 8 funds sold all Sophiris Bio Inc shares owned while 5 reduced positions. 5 funds bought stakes while 5 increased positions. They now own 1.50 million shares or 31.22% less from 2.18 million shares in 2016Q1.
Citadel Advsr Limited Liability Co reported 49,176 shares or 0% of all its holdings. Jane Street Lc accumulated 27,176 shares or 0% of the stock. The California-based Palo Alto Invsts Ltd Company has invested 0.08% in Sophiris Bio Inc (NASDAQ:SPHS). Vanguard Gru accumulated 331,000 shares or 0% of the stock. Commercial Bank Of Montreal Can accumulated 0% or 1,632 shares. Royal Commercial Bank Of Canada holds 5,971 shares or 0% of its portfolio. Kcg Holdings has 17,013 shares for 0% of their US portfolio. Rock Springs Capital Management Limited Partnership, a Maryland-based fund reported 490,000 shares. Wells Fargo And Com Mn owns 3,800 shares or 0% of their US portfolio. Morgan Stanley has 225 shares for 0% of their US portfolio. Creative Planning last reported 900 shares in the company. Ladenburg Thalmann Services has 600 shares for 0% of their US portfolio. The New York-based Fny Managed Accounts Llc has invested 0% in Sophiris Bio Inc (NASDAQ:SPHS). National Bank Of America De holds 0% or 1,222 shares in its portfolio. Bank & Trust Of New York Mellon has invested 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS).

More important recent Sophiris Bio Inc (NASDAQ:SPHS) news were published by: Prnewswire.com which released: “Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering” on May 06, 2016, also Prnewswire.com published article titled: “Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as …”, Prnewswire.com published: “Sophiris Bio Prices Public Offering of Common Shares and Warrants” on August 23, 2016. More interesting news about Sophiris Bio Inc (NASDAQ:SPHS) was released by: Prnewswire.com and their article: “Sophiris Bio Closes Underwritten Public Offering” with publication date: August 26, 2016.

SPHS Company Profile

Sophiris Bio Inc., incorporated on May 1, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on developing products for the treatment of urological diseases. The Firm is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment